AMAG Updates Feraheme Label To Include Safety Risks

Law360, New York (November 30, 2010, 5:32 PM EST) -- AMAG Pharmaceuticals Inc. has reached an agreement with the U.S. Food and Drug Administration to update the label for its injectable iron deficiency treatment Feraheme to include adverse reactions identified after the drug gained market approval.

The FDA signed off on AMAG's new product label for Feraheme on Nov. 24, AMAG said Monday.

Feraheme, AMAG's brand name for ferumoxytol, is an injection used to treat anemia in patients with chronic kidney disease. The company had been negotiating with the FDA over safety concerns in the wake...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.